Law360, New York (August 18, 2009, 2:50 PM ET) -- Rochester Drug Co-Operative Inc. has hit Boehringer Ingelheim International GmbH with a putative class action alleging the company took repeated steps, including sham patent litigation and anti-competitive agreements, to unlawfully preserve a monopoly on Parkinson's disease treatment Mirapex.
In a complaint filed Monday in the U.S. District Court for the Western District of Pennsylvania, the drug co-op accuses the drugmaker and its U.S. affiliate Boehringer Ingelheim Pharmaceuticals Inc. of a series of unlawful actions designed to extend a monopoly on the sale of Mirapex.
Boehringer filed...
Drug Co-Op Accuses Boehringer Of Mirapex Monopoly
To view the full article, take a free trial now.
